Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071981 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT00071981 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 175 participants.
The verdict
NCT00071981, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma peptides from cytotoxic T cells and helper T cells to see how well they work in treating patients with metastatic melanoma.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL melanoma helper peptide vaccine
- BIOLOGICAL multi-epitope melanoma peptide vaccine
- BIOLOGICAL tetanus peptide melanoma vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2005-05-09 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071981
The ClinicalTrials.gov registry entry for NCT00071981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which sargramostim is the first listed.
NCT00071981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071981 about?
NCT00071981 is a clinical study titled "Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma peptides from cytotoxic T cells and helper T cells to see how well they work in treating patients with me...
What is the current status of trial NCT00071981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2005-05-09. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00071981?
The interventions under investigation include: sargramostim (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), melanoma helper peptide vaccine (BIOLOGICAL), multi-epitope melanoma peptide vaccine (BIOLOGICAL), tetanus peptide melanoma vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00071981?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.